Orphan designation was granted by the FDA to Curis (CRIS) Inc’s emavusertib for the treatment of primary central nervous system lymphoma, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
